TRML – tourmaline bio, inc. (US:NASDAQ)
Stock Stats
News
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Guggenheim.
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day [Yahoo! Finance]
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
Form 8-K Tourmaline Bio, Inc. For: Dec 10
Form 8-K Tourmaline Bio, Inc. For: Dec 10
Form EFFECT Tourmaline Bio, Inc.
Form SC 13G/A Tourmaline Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A Tourmaline Bio, Inc. Filed by: Blue Owl Capital Holdings LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.